Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pseudoexfoliation syndrome Indication Strategy Report 2026: LOXL1, Trials and Deals
3 August 2026
2026 Pseudoexfoliation syndrome indication strategy covering epidemiology, LOXL1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Orbital lymphangioma Indication Strategy Report 2026: PIK3CA, Trials and Deals
3 August 2026
2026 Orbital lymphangioma indication strategy covering epidemiology, PIK3CA biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Thyroid eye disease chronic inactive Indication Strategy Report 2026: IGF1R, Trials and Deals
3 August 2026
2026 Thyroid eye disease chronic inactive indication strategy covering epidemiology, IGF1R biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Idiopathic orbital inflammation Indication Strategy Report 2026: CD20, Trials and Deals
3 August 2026
2026 Idiopathic orbital inflammation indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Dysthyroid optic neuropathy Indication Strategy Report 2026: IGF1R, Trials and Deals
3 August 2026
2026 Dysthyroid optic neuropathy indication strategy covering epidemiology, IGF1R biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Peripheral ulcerative keratitis Indication Strategy Report 2026: CD20, Trials and Deals
3 August 2026
2026 Peripheral ulcerative keratitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Posterior scleritis Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Posterior scleritis indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Iridocorneal endothelial syndrome Indication Strategy Report 2026: VEGF, Trials and Deals
3 August 2026
2026 Iridocorneal endothelial syndrome indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Thiel-Behnke corneal dystrophy Indication Strategy Report 2026: TGFBI, Trials and Deals
3 August 2026
2026 Thiel-Behnke corneal dystrophy indication strategy covering epidemiology, TGFBI biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Reis-Bucklers corneal dystrophy Indication Strategy Report 2026: TGFBI, Trials and Deals
3 August 2026
2026 Reis-Bucklers corneal dystrophy indication strategy covering epidemiology, TGFBI biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Macular corneal dystrophy Indication Strategy Report 2026: CHST6, Trials and Deals
3 August 2026
2026 Macular corneal dystrophy indication strategy covering epidemiology, CHST6 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Meesmann corneal dystrophy Indication Strategy Report 2026: KRT12, Trials and Deals
3 August 2026
2026 Meesmann corneal dystrophy indication strategy covering epidemiology, KRT12 biology, active trials, transactions, unmet need, competition and market…